2025-11-12T09:28:38-06:00 2024-12-31 871353108 EISNER ADVISORY GROUP LLC 733 THIRD AVENUE NEW YORK NY 100172703 990 2024-01-01 872622250 ADVANCIUM HEALTH NETWORK INC ADVA 2125838281 345 PARK AVENUE SOUTH 4TH FLOOR NEW YORK NY 10010 MARK VEICH CHIEF EXECUTIVE OFFICER 2125838281 2025-11-12 1 1 CANDICE METH P01306891 2129498700 2024 2025-03-06 01:10:19Z MARK VEICH 345 PARK AVENUE SOUTH 4TH FLOOR NEW YORK NY 10010 14292352 0 X WWW.ADVANCIUMHEALTH.ORG X 2021 DE DEVELOP EXPERTISE TO ADVANCE & APPLY SOLUTIONS TO ADDRESS THE NEEDS OF UNDERSERVED COMMUNITIES. 6 6 9 6 -8758 0 16883964 13696852 0 0 1015 -12614434 82358 0 16967337 1082418 1053494 1883322 0 0 1546940 2306284 0 240000 360670 2700560 2709292 5300994 7138898 11666343 -6056480 17991568 4785014 5995157 367459 11996411 4417555 X SEE SCHEDULE O 0 1 5015884 1883322 ADVANCIUM HEALTH NETWORK, INC. IS A MISSION-DRIVEN CHARITABLE ORGANIZATION COMMITTED TO ELIMINATING BARRIERS IN HEALTHCARE THROUGH A UNIQUE MODEL THAT COMBINES THE EXPERTISE OF FOR-PROFIT LEADERSHIP WITH NON-PROFIT MOTIVATIONS. THROUGH THE SUPPORT OF OUR PARTNERS, INDUSTRY EXPERTS, AND CHARITABLE DONORS, WE'RE TACKLING HEALTHCARE'S MOST CHALLENGING GAPS AND UNMET NEEDS ACROSS THE INDUSTRY - FROM EARLY-STAGE INNOVATION, TO PEDIATRICS AND RARE DISEASE. ADVANCIUM HEALTH NETWORK IS COMMITTED TO A POSITIVE IMPACT ON HUMAN HEALTH. 5015884 1 1 0 0 0 0 0 0 0 0 1 1 0 1 0 1 0 1 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 X 16 0 1 9 1 0 0 0 0 0 0 0 0 0 0 0 0 X 6 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 0 0 0 NY X LINDSEY REYNOLDS 2125838281 345 PARK AVENUE SOUTH 4TH FLOOR NEW YORK NY 10010 MARK VEICH PRESIDENT 40.00 X X 0 0 0 OLIVIER ELEMENTO SECRETARY 1.00 X X 0 0 0 JEFFREY KAPLAN TO 424 TREASURER 1.00 X X 0 0 0 GARY BREWSTER AS OF 424 DIRECTOR 1.00 X 0 0 0 MICHELE CLEARY DIR TO 524 CHIEF SCIENTIFIC OFFICER (AS OF 6/24) 40.00 X X 327670 0 5205 YUNG LIE AS OF 624 DIRECTOR 1.00 X 0 0 0 RON MITCHELL DIRECTOR 1.00 X 0 0 0 LAURIE ZEPHYRIN DIRECTOR 1.00 X 0 0 0 SHAWN DAVIS TO 224 SVP & COO 40.00 X 246644 0 4947 LINDSEY REYNOLDS DIRECTOR, FINANCE 40.00 X 267949 0 21544 EMMA MORAN EVANS DIRECTOR, COBICURE MED TECH 40.00 X 271338 0 60160 MAUREEN REYES DIRECTOR, STRATEGY & OPS 40.00 X 291194 0 26728 ROBERT OLAN VP BUSINESS DEVELOPMENT 40.00 X 254008 0 40090 JYOTI PATEL DIRECTOR BUSINESS OPS & MARKETING 40.00 X 215354 0 18845 1874157 0 177519 7 0 1 0 MORGAN LEWIS & BOCKIUS LLP 101 PARK AVENUE NEW YORK NY 10178 LEGAL SERVICES 554314 HARMONIZED MARKETING LLC 400 EAST 66TH STREET 17C NEW YORK NY 10065 CONSULTING - BRANDING 286810 DAD STRATEGIES LLC 340 E 80TH STREET 18E NEW YORK NY 10075 CONSULTING - FUNDRAISING 240000 RSM US LLP 5155 PAYSPHERE CIRCLE CHICAGO IL 60674 ACCOUNTING SUPPORT SERVICES 221304 UPPER WEST SIDE STRATEGIES LLC 317 WEST 103RD STREET NEW YORK NY 10025 CONSULTING - STRATEGY & PROGRAM 128744 6 13696852 8855203 13696852 90933 -8758 99691 504567 512380 12697554 -7813 -12697554 -12705367 -12705367 1082418 0 -8758 -12605676 X 1883322 1883322 873959 498157 375802 1152696 765497 387199 14685 12901 1784 145678 105226 40452 119266 70925 48341 370787 163295 207492 213002 213002 240000 240000 8000 8000 927171 707107 220064 16033 14412 1557 64 171984 80365 91619 431958 431958 158391 55788 19086 83517 254675 225642 29033 4430 4430 122539 122539 LICENSES AND FEES 27151 1289 17806 8056 3171 3171 7138898 5015884 1762344 360670 408497 1842582 1598125 1951528 6901 3621470 25871 326479 185972 31010 4430 12036997 26580 497468 0 248112 17991568 4785014 5731157 203459 264000 164000 5995157 367459 X 11269104 4417555 727307 0 11996411 4417555 17991568 4785014 X -6056480 -1522376 X 0 1 X 1 0 X 50000 3430000 16883964 13696852 34060816 50000 3430000 16883964 13696852 34060816 15834042 18226774 74 1068 99691 100833 -8758 -8758 82358 82358 34235249 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - EVENT SPONSORSHIPS - 2023 AMOUNT: $ 82,358. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 31010 4430 26580 26580 NON-READILY MARKETABLE SECURITIES 324312 F LIMITED PARTNERSHIPS 173156 F 497468 LABORATORY EQUIPMENT 248112 248112 X 1796399 244357 477624 721981 1074418 8000 8000 1082418 9375255 244357 2000000 2244357 7130898 8000 8000 7138898 PART X, LINE 2: THE ORGANIZATION IS SUBJECT TO THE PROVISIONS OF THE FINANCIAL ACCOUNTING STANDARDS BOARD'S (THE "FASB") ACCOUNTING STANDARDS CODIFICATION ("ASC") TOPIC 740, INCOME TAXES, AS IT RELATES TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. BECAUSE OF THE ORGANIZATION'S GENERAL TAX-EXEMPT STATUS, MANAGEMENT BELIEVES ASC TOPIC 740 HAS NOT HAD, AND IS NOT EXPECTED TO HAVE, A MATERIAL IMPACT ON THE ORGANIZATION'S CONSOLIDATED FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: GAIN ON TERMINATION OF LEASE 477,624. PART XII, LINE 2D - OTHER ADJUSTMENTS: LOSS ON UNCOLLECTIBLE ACCOUNTS 2,000,000. X X 1 DAD STRATEGIES LLC 340 E 80TH STREET 18E NEW YORK NY 10075 FUND-RAISING CONSULTANT 0 0 240000 -240000 240000 -240000 NY 1 POLYVASCULAR INC 6501 NAVIGATION BLVD SUITE O2 HOUSTON TX 77011 471238096 FOR PROFIT 1040283 0 RESEARCH AND DEVELOPMENT THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET 5TH FLOOR PHILADELPHIA PA 19104 231352685 501(C)(3) 169000 0 RESEARCH AND DEVELOPMENT BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 70030 741613878 501(C)(3) 135000 0 RESEARCH AND DEVELOPMENT ANN & ROBERT H LURIE CHILDREN'S HOSPITAL OF CHICAGO 225 E CHICAGO AVE BOX 282 CHICAGO IL 60611 362170833 501(C)(3) 130000 0 RESEARCH AND DEVELOPMENT THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL 700 CHILDRENS DRIVE COLUMBUS OH 43205 010782751 501(C)(3) 129605 0 RESEARCH AND DEVELOPMENT CHILDREN'S NATIONAL MEDICAL CENTER 111 MICHIGAN AVENUE NW WASHINGTON DC DC 20010 521640403 501(C)(3) 128996 0 RESEARCH AND DEVELOPMENT BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 85 BROADWAY STREET REDWOOD CITY CA 94063 941156365 501(C)(3) 118438 0 RESEARCH AND DEVELOPMENT COLUMBIA UNIVERSITY 622 W 113TH ST NEW YORK NY 10025 135598093 501(C)(3) 32000 0 RESEARCH AND DEVELOPMENT 7 1 PART I, LINE 2: THE ORGANIZATION REQUIRES GRANTEES TO ADHERE TO SPECIFIED TERMS AND CONDITIONS, INCLUDING THE SUCCESSFUL COMPLETION OF MILESTONES, WHERE SPECIFIED. ALL GRANT DISBURSEMENTS ARE CONTINGENT ON ACCEPTANCE OF GRANT TERMS, AS WELL AS DOCUMENTED PROGRESS OF SATISFACTION OF APPLICABLE MILESTONES. X 1 1 1 0 0 0 0 0 0 1 0 MICHELE CLEARY DIR TO 524 CHIEF SCIENTIFIC OFFICER (AS OF 6/24 251875 0 75795 0 0 0 4228 0 977 0 332875 0 0 0 EMMA MORAN EVANS DIRECTOR, COBICURE MED TECH 225578 0 45760 0 0 0 4922 0 55238 0 331498 0 0 0 MAUREEN REYES DIRECTOR, STRATEGY & OPS 242194 0 49000 0 0 0 5880 0 20848 0 317922 0 0 0 ROBERT OLAN VP BUSINESS DEVELOPMENT 209908 0 44100 0 0 0 3882 0 36208 0 294098 0 0 0 LINDSEY REYNOLDS DIRECTOR, FINANCE 222189 0 45760 0 0 0 4922 0 16622 0 289493 0 0 0 SHAWN DAVIS TO 224 SVP & COO 69324 0 0 0 177320 0 1400 0 3547 0 251591 0 0 0 JYOTI PATEL DIRECTOR BUSINESS OPS & MARKETING 179314 0 36040 0 0 0 0 0 18845 0 234199 0 0 0 PART I, LINE 1A THE ORGANIZATION IS COMMITTED TO FOSTERING A HEALTHY AND PRODUCTIVE WORK ENVIORNMENT FOR ITS EMPLOYEES, AND HAS PROVIDED HEALTH CLUB DUES FOR ITS STAFF. PART I, LINE 4A THE FOLLOWING INDIVIDUAL RECEIVED A SEVERANCE PAYMENT WHICH IS INCLUDED IN SCHEDULE J, PART II, COLUMN B(III): SHAWN DAVIS - $177,320 PART I, LINE 8 THE PRESIDENT APPROVED AND PAID REASONABLE DISCRETIONARY BONUSES BASED ON STAFF PERFORMANCE DURING THE YEAR. X 1 512380 COMPARABLE SALES X 3 324312 FMV VALUATION STUDY X 2 173156 FMV VALUATION STUDY X SEE SCH M PG 2 1 8357735 COST 0 1 0 PART I, COLUMN (B): BASED ON THE NUMBER OF CONTRIBUTIONS RECEIVED SCHEDULE M, PART 1, LINE 25 FORGIVENESS OF LOANS AND ACCRUED INTEREST FORM 990, PART I, LINE 1 TRANSFORM HEALTHCARE THROUGH NOVEL COLLABORATIONS TO ADVANCE AND APPLY INNOVATIVE SOLUTIONS TO ADDRESS THE NEEDS OF UNDERSERVED POPULATIONS AND COMMUNITIES. ADVANCIUM AIMS TO FUND ACTIVITIES, TECHNOLOGIES AND HEALTHCARE INITIATIVES WITH A FOCUS ON PEDIATRIC MEDICAL TECHNOLOGIES AND THERAPEUTICS. FORM 990, PART III, LINE 3 IN 2024, THE ORGANIZATION DISCONTINUED PLANS TO OPERATE A LABORATORY FACILITY AS PART OF A STRATEGIC SHIFT FROM LONG-TERM LABORATORY MANAGEMENT TO FOCUS ON ADVANCING INNOVATIONS IN PEDIATRIC RARE DISEASES. THE ORGANIZATION TRANSITIONED THE RELATED SPACE AND EQUIPMENT TO EXTERNAL PARTNERS. THIS TRANSITION RESULTED IN THE DIVESTITURE OF CERTAIN FIXED ASSETS AND A CORRESPONDING DECREASE IN TOTAL ASSETS REPORTED AT YEAR-END. FORM 990, PART V, LINE 2A THE ORGANIZATION'S EMPLOYEES ARE EMPLOYED BY A PROFESSIONAL EMPLOYMENT ORGANIZATION ("PEO"), AND ACCORDINGLY, THE FORM W-3 AND ALL W-2'S ARE FILED THROUGH THE PEO. FORM 990, PART VI, SECTION B, LINE 11B THE AUDIT COMMITTEE AND FULL BOARD OF DIRECTORS REVIEW AND APPROVE THE FORM 990 PRIOR TO ITS SUBMISSION TO THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S CONFLICT OF INTEREST POLICY APPLIES TO DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND KEY EMPLOYEES WHO ARE REQUIRED TO ANNUALLY REVIEW AND ACKNOWLEDGE THEIR COMPLIANCE WITH THE POLICY. SUCH INDIVIDUALS ALSO COMPLETE AN ANNUAL DISCLOSURE FORM OF RELEVANT FINANCIAL AND BUSINESS INTERESTS, AND HAVE AN ONGOING DUTY TO DISCLOSE ANY POTENTIAL INTERESTS IN A TRANSACTION UNDER CONSIDERATION BY THE BOARD OF DIRECTORS. INTERESTED PERSONS ARE RECUSED FROM CONSIDERATION OF AND VOTING ON ANY TRANSACTION IN WHICH THEY HAVE CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE ORGANIZATION IS IN THE PROCESS OF CREATING A FORMAL COMPENSATION SETTING POLICY WHICH WILL BE APPROVED IN 2025. IN THE COURSE OF BUSINESS, THE ORGANIZATION'S BOARD OF DIRECTORS HAS HAD OVERSIGHT FOR THIS PROCESS. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND CONSOLIDATED FINANCIAL STATEMENTS ARE AVAILABLE UPO0N REQUEST. FORM 990, PART IX, LINE 11G PROGRAM STRATEGY CONSULTING: PROGRAM SERVICE EXPENSES 324,720. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 324,720. MARKETING CONSULTING: PROGRAM SERVICE EXPENSES 94,911. MANAGEMENT AND GENERAL EXPENSES 220,064. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 314,975. SCIENTIFIC ADVISORY CONSULTING: PROGRAM SERVICE EXPENSES 215,060. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 215,060. ENVIRONMENTAL HEALTH AND SAFETY CONSULTING: PROGRAM SERVICE EXPENSES 42,405. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 42,405. OTHER: PROGRAM SERVICE EXPENSES 30,011. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 30,011. FORM 990, PART XI, LINE 9: LOSS ON UNCOLLECTIBLE ACCOUNTS -2,000,000. GAIN ON TERMINATION OF LEASE 477,624. COBICURE LLC 345 PARK AVENUE SOUTH NEW YORK NY 10010 874299453 MEDICAL RESEARCH NY 0 0 ADVANCIUM HEALTH NETWORK INC CURE INNOVATION LABS LLC 345 PARK AVENUE SOUTH NEW YORK NY 10010 931413393 MEDICAL RESEARCH NY 3281930 248672 ADVANCIUM HEALTH NETWORK INC LUKA SHAI FOUNDATION LLC 345 PARK AVENUE SOUTH NEW YORK NY 10010 884322833 MEDICAL RESEARCH NY 1426733 1531596 ADVANCIUM HEALTH NETWORK INC BREAK INTO THE BOARDROOM LLC 345 PARK AVENUE SOUTH NEW YORK NY 10010 872622250 MEDICAL RESEARCH NY 6901 6901 ADVANCIUM HEALTH NETWORK INC